<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-90210</identifier>
<setSpec>1137-6627</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">The role of the DOG1 antibody in the diagnosis of gastrointestinal stromal tumours &#150; GIST</dc:title>
<dc:description xml:lang="en">Gatrointestinal stromal tumours (GIST) harbouroncogenic mutations in tyrosin kynases receptors(RTKs) including KIT and PDGFRA. The inhibition ofthis activity has been regarded as the primary target forthe treatment of these patients. Diagnosis of GIST relieson c-KIT inmunoreactivity; however there is a 4-15% ofGISTs that are C-KIT negative which may lead to underdiagnosisof GISTs and possible withholding of therapy.The novel gene DOG1 has been found overexpressedin GISTs and has potential as a diagnostic markerfor GISTs showing even more sensitivity (Se) and specificity(Sp) than c-KIT for the diagnosis of these tumors.In this study we compared the (Se) and (Sp) of DOG1 intypical and atypical GISTs (c-KIT positive or negative)with c-KIT and other mesenchymal neoplasms in thedifferential diagnosis of GISTsWe examined 40 GIST (39 showed inmunoreactivityfor c-KIT and one was c-KIT negative) and anotherseven fusiform tumors. An inmunohistochemical panelwas performed with c-KIT, CD34, smooth muscle actin,DOG1 and S100 antibodies on both types of neoplasms.The overall Se and Sp of DOG1 and KIT in GISTswere nearly identical: 100 and 97,5%. Negativity forDOG1 was observed in all fusiform mesenchymal neoplasms.DOG1 is highly expressed in GIST and its expressionseems quite specific for these tumours when thedifferential diagnosis includes another mesenchymalneoplasms.DOG1 should be added to the diagnostic panel evaluatingGISTs(AU)</dc:description>
<dc:creator>Martínez-Peñuela Virseda, J. M</dc:creator>
<dc:creator>Amat Villegas, I</dc:creator>
<dc:creator>Mercado, M. R</dc:creator>
<dc:creator>Martínez-Peñuela Marco, A</dc:creator>
<dc:creator>Gómez Dorronsoro, M. L</dc:creator>
<dc:creator>Rodríguez Pérez, I</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los tumores del estroma gastrointestinal (GIST)poseen mutaciones en los genes del receptor de la tirosínquinasa (RTKs) KIT y PDGFRA. La posibilidad debloquear esta actividad ha significado una nueva esperanzaterapéutica. El diagnóstico de GIST recae en laexpresión inmunohistoquímica del c-KIT, pero un 4-15%son c-KIT negativos (aún en presencia de mutación), ysin embargo estos pacientes podrían beneficiarse deltratamiento con inhibidores tirosín quinasa (TKIs).El DOG1 es un nuevo anticuerpo cuya sensibilidady especificidad parece ser superior o igual a la del c-KIT.El objetivo de este trabajo es evaluar la sensibilidad(Se) y especificidad (Sp) de DOG1 en GIST de tipo usual(c-KIT positivos), de tipo inusual (c-KIT negativos) yfrente a otros tumores fusocelulares mesenquimales, ycomparar la validez diagnóstica del DOG1 frente al c-KIT.Estudiamos 40 GIST, 39 c-KIT positivos y un c-KITnegativo. Se realizó un panel inmunohistoquímico conlos anticuerpos: c-KIT, CD34, actina músculo liso, DOG1y S100, en los GIST como en siete tumores fusocelulares.La Se y Sp de GIST para DOG1 fue del 100 y 97,5%para c-KIT. La inmunoreactividad para DOG1 en todoslos tumores fusocelulares fue negativa. La validez diagnósticade DOG1 y C-KIT fue similar a la hora de detectarGIST y no GIST.DOG1 es un marcador específico y sensible para eldiagnóstico y diagnóstico diferencial de GISTs (es capazde detectar algunos GIST sin mutación en RTK).El DOG1 debería de formar parte del panel inmunohistoquímicopara el diagnóstico de GIST(AU)</dc:description>
<dc:source>An Sist Sanit Navar;34(2): 245-251, mayo-ago. 2011. tab</dc:source>
<dc:identifier>ibc-90210</dc:identifier>
<dc:title xml:lang="es">Estudio del anticuerpo DOG1 en el diagnóstico de tumores del estroma gastrointestinal &#150; GIST</dc:title>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5911^s22053</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d38616^s22016</dc:subject>
<dc:subject>^d38616^s22027</dc:subject>
<dc:subject>^d5911^s22080</dc:subject>
<dc:subject>^d5911^s22016</dc:subject>
<dc:subject>^d38616^s22059</dc:subject>
<dc:subject>^d5911^s22027</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d5911^s22034</dc:subject>
<dc:subject>^d38616^s22054</dc:subject>
<dc:subject>^d38616^s22032</dc:subject>
<dc:subject>^d38616^s22053</dc:subject>
<dc:subject>^d5911^s22054</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d38616^s22080</dc:subject>
<dc:subject>^d5911^s22009</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:type>article</dc:type>
<dc:date>201108</dc:date>
</metadata>
</record>
</ibecs-document>
